Ethicon, Inc.

111 articles about Ethicon, Inc.

• ETHICON LAUNCHES NEXT GENERATION ECHELON™ 3000 STAPLER DESIGNED FOR EXCEPTIONAL ACCESS AND CONTROL

  6/6/2022

  Highly Anticipated Stapler Offers Greatest Articulation Span and Widest Jaw Aperture Among Leading Handheld Staplers.

• 

  New Freedoms Could Catapult J&J Pipeline Following Split

  11/19/2021

  A week after announcing its intention to spin off its consumer health division, J&J revealed ambitious plans for its pharmaceutical business.

• Ethicon Expands Advanced Biopolar Energy Portfolio With Launch Of ENSEAL X1 Curved Jaw Tissue Sealer

  6/21/2021

  Ethicon announced the launch of the ENSEAL X1 Curved Jaw Tissue Sealer, a new advanced bipolar energy device that increases procedural efficiency1 and provided stronger sealing2 and better access to more tissue than LigaSure™ Maryland.3 The device is indicated for colorectal, gynecological, bariatric surgery and thoracic procedures.

• U.S. FDA Grants Ethicon Breakthrough Device Designation for Monarch-enabled NeuWave Microwave Ablation Technology

  7/30/2020

   Ethicon*, part of the Johnson & Johnson Medical Devices Company**, announced the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for transbronchial microwave ablation technology using robotic-assisted bronchoscopy, which is currently under development.  

• Prisma Health Collaborates with Ethicon Inc. to Manufacture and Distribute the VESper™ Ventilator Expansion Splitter Device that is Authorized for Emergency Use Only During the COVID-19 Pandemic

  4/6/2020

  Prisma Health announced that it is collaborating with Ethicon Inc., part of the Johnson & Johnson Medical Devices Companies, to make and distribute a ventilator expansion device, called the VESper™ Ventilator Expansion Splitter.

• 

  Top Biopharma M&As in 2019

  1/10/2020

  The year was marked by mergers and acquisitions both big and small. Although not comprehensive, here’s a look at some of the top deals for 2019.
• 

  J&J's Ethicon and Spain's Grifols Release 1st Product Out of 10-Year Collaboration Deal

  6/20/2019

  The sealant was developed by Grifols and combines two plasma proteins, fibrinogen and thrombin. The spray is administered with New Jersey-based Ethicon’s airless spray device.

• MyPhillyLawyer Helps Secure $80 Million Victory for Transvaginal Mesh Patient

  6/3/2019

  The verdict was delivered in the Philadelphia Court of Common Pleas on May 17, 2019 and also included $50 million in punitive damages.

• 

  Takeda Divests Eye Drug to Novartis for $5.3 Billion

  5/9/2019

  The sale of Xiidra to Novartis and TachoSil to Ethicon is part of Takeda's strategy to pare down debt from its $62 billion acquisition of Shire.

• Takeda Simplifies Portfolio and Accelerates Deleveraging Through Two Divestitures

  5/8/2019

  Takeda Pharmaceutical Company Limited announced that it has entered into agreements to divest its Xiidra® 5% product to Novartis and its TachoSil® Fibrin Sealant Patch to Ethicon as part of its strategy to focus on business areas core to its long-term growth and facilitate rapid deleveraging following its acquisition of Shire.

• Johnson & Johnson Announces Completion of Acquisition of Auris Health, Inc.

  4/1/2019

  Johnson & Johnson (NYSE: JNJ) announced today that Ethicon, Inc., has completed the acquisition of Auris Health, Inc. for approximately $3.4 billion in cash

• Johnson & Johnson Announces Agreement to Acquire Auris Health, Inc.

  2/13/2019

  Auris Health's Robotic Platform Expands Johnson & Johnson's Digital Surgery Portfolio

• ETHICON LAUNCHES COMPREHENSIVE SOLUTION FOR BARIATRIC REVISION SURGERY 

  9/26/2018

  Portfolio of Products, Education and Training to Help Surgeons Handle Challenging Reoperations

• Johnson & Johnson Announces Binding Offer from Fortive Corporation to Acquire Advanced Sterilization Products (ASP)

  6/6/2018

  Johnson & Johnson announced that it has received a binding offer from Fortive Corporation to acquire its Advanced Sterilization Products (ASP) business, a division of Ethicon, Inc.

• New Study Finds Powered Stapler Use Is Associated With Reduced Rates Of Bleeding Complications In Thoracic Surgery For Lung Cancer

  4/30/2018

  Bleeding complications dropped by nearly half when surgeons used a powered stapler as opposed to a manual device in what researchers say is the first real-world assessment of the two technologies in video-assisted thoracoscopic surgery (VATS) for lung cancer.

• 

  J&J’s Ethicon Accuses Intuitive Surgical of Infringing Patents With the Endowrist Cutter-Stapler

  2/7/2018

  The June 30, 2017 lawsuit asserts that the EndoWrist violates seven Ethicon patents.

• New Absorbable Adjunctive Hemostat From Ethicon Helps Surgeons Control Disruptive Bleeding More Efficiently

  1/9/2018

  SURGICEL Powder is designed to address continuous, broad-surface oozing and stop bleeding fast.

• Ethicon's BIOPATCH Protective Disk With CHG Meets New CDC Recommendation and Continues as the Standard of Care to Reduce Intravascular Catheter-Related Blood Stream Infections

  11/10/2017

  BIOPATCH is the only IV dressing proven in multiple meta-analyses and randomized controlled trials to reduce risk of central line associated bloodstream infections in patients with central and arterial lines.

• Ethicon Showcases Leading Edge Solutions Beyond The O.R. To Empower Patients And Providers In Fight Against Obesity At ObesityWeek™ 2017

  10/31/2017

  Now, Ethicon is partnering with Johnson & Johnson Health & Wellness Solutions to introduce a new digital platform and smartphone app offering resources and decision-making tools for patients considering weight loss surgery

• Johnson & Johnson's Ethicon Hit With $57 Million Verdict in Pennsylvania Pelvic Mesh Case

  9/8/2017